U.S. markets close in 2 hours 27 minutes

Eli Lilly and Company (LLY.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
312.05+3.50 (+1.13%)
As of 05:20PM CEST. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close308.55
Bid310.25 x 30000
Ask310.55 x 30000
Day's Range310.80 - 314.95
52 Week Range257.60 - 373.50
Avg. Volume351
Market Cap297.18B
Beta (5Y Monthly)0.35
PE Ratio (TTM)48.30
EPS (TTM)6.46
Earnings DateApr 27, 2023
Forward Dividend & Yield4.27 (1.40%)
Ex-Dividend DateFeb 14, 2023
1y Target Est399.74
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for LLY.F

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Investor's Business Daily

      The Government Move That Could Drive Obesity Drugs — And Lilly, Novo Shares

      The WHO will consider adding obesity treatments to its "essential medicines list." The move could help shares of Eli Lilly and Novo Nordisk.

    • Motley Fool

      3 Dividend Stocks That Have Been Paying Investors Since the 1800s

      Three businesses that have not only been around for more than a century but have also been paying dividends going back to the 1800s are Eli Lilly (NYSE: LLY), ExxonMobil (NYSE: XOM), and the Toronto-Dominion Bank (NYSE: TD). Healthcare giant Eli Lilly has been paying a dividend since 1885.

    • Reuters

      UPDATE 1-Boehringer's profit up as Jardiance gains offset higher costs

      German unlisted drugmaker Boehringer Ingelheim said on Wednesday its operating income rose 1.4% in 2022, as more prescriptions of diabetes drug Jardiance trumped higher energy and development costs. Family-owned Boehringer said in its annual report that full-year operating income came in at 4.77 billion euros ($5.17 billion), up from 4.71 billion a year earlier. The Jardiance group of products, managed in a partnership with Eli Lilly, made 5.8 billion euros in sales, a currency-adjusted surge of 39.1%.